ESPBD与EST治疗肝硬化合并胆总管结石患者疗效比较*

doi:10.3969/j.issn.1672-5069.2023.06.037

摘要/Abstract

摘要： 目的研究采用内镜下十二指肠乳头括约肌小切开联合球囊扩张术(ESPBD)与内镜下十二指肠乳头括约肌切开术(EST)治疗肝硬化合并胆总管结石患者的疗效。方法 2018年3月～2022年3月我院收治的代偿期肝硬化合并胆总管结石患者112例,其中56例对照组接受EST治疗,另56例观察组接受ESPBD治疗。采用ELISA法检测血清皮质醇(COR)、去甲肾上腺素(NE)和肾上腺素(E)水平。结果观察组一次取石成功率为96.4%,显著高于对照组为80.4%(P＜0.05);观察组术中出血量、手术时间、肛门排气时间和术后住院时间分别为(25.3±3.1)mL、41.8±5.1)min、(24.3±4.6)h和(8.1±1.6)d,与对照组【分别为(27.9±2.8)mL、(44.9±4.9)min、(25.7±6.9)h和(7.8±2.1)d】比,差异无统计学意义(P>0.05);在术后7 d,观察组血清TBIL、ALT、ALB和GGT水平分别为(15.4±3.6)μmol/L、(29.6±5.7)U/L、(36.3±6.9)g/L和(94.2±5.2)U/L,与对照组的(14.8±2.9)μmol/L、(30.2±6.8)U/L、(37.1±5.8)g/L和(96.1±6.3)U/L比,无显著性差异(P＞0.05);观察组血清COR、NE和E水平分别为(129.7±18.2)pg/mL、(415.1±51.6)pg/mL和(24.4±3.9)pg/mL,与对照组的(135.9±21.6)pg/mL、(422.7±53.9)pg/mL和(25.9±4.1)pg/mL比,无显著性差异(P>0.05);术后,观察组并发症,如切口感染、胰腺炎、腹腔出血、胆漏和高淀粉酶血症发生率为14.3%,显著低于对照组的30.4%(P＜0.05)。结论与EST术比,采用ESPBD治疗肝硬化合并胆总管结石患者能提高一次性取石成功率,减少术后并发症的发生,而不会增加应急反应。

关键词: 胆总管结石, 肝硬化, 内镜下十二指肠乳头括约肌切开术, 内镜下十二指肠乳头括约肌小切开联合球囊扩张术, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy of limited endoscopic sphincterotomy with balloon dilation (ESPBD) and endoscopic sphincterotomy (EST) in the treatment of patients with liver cirrhosis common bile duct stones. Methods 112 patients with compensated liver cirrhosis and choledolithiasis were admitted to our hospital between March 2018 and March 2022, and 56 patients in the control were treated with EST and another 56 in the observation group were treated with ESPBD. Serum cortisol (COR), norepinephrine (NE) and epinephrine (E) levels were detected by ELISA. Results The successful rate of one time stone removal in the observation group was 96.4%, significantly higher than 80.4% in the control group (P <0.05); the intra-operational blood loss, operation time, exhaust time and hospital stay in the observation group were(25.3±3.1)mL, 41.8±5.1)min, (24.3±4.6)h and (8.1±1.6)d, not significantly different compared to [(27.9±2.8)mL, (44.9±4.9)min, (25.7±6.9)h and (7.8±2.1)d] in the control (P>0.05); 7 day after operation, total serum bilirubin, serum alanine aminotransferase, albumin and glutamyl transpeptidease levels in the observation were (15.4±3.6)μmol/L, (29.6±5.7)U/L, (36.3±6.9)g/L and (94.2±5.2)U/L, not significantly different compared to (14.8±2.9)μmol/L, (30.2±6.8)U/L, (37.1±5.8)g/L and (96.1±6.3)U/L in the control (P＞0.05); serum COR, NE and E levels were (129.7±18.2)pg/mL, (415.1±51.6)pg/mL and (24.4±3.9)pg/mL, not significantly different compared to (135.9±21.6)pg/mL,(422.7±53.9)pg/mL and (25.9±4.1)pg/mL in the control (P>0.05); post-operationally, the incidence of complications, such as infection, pancreatitis, intraperitoneal bleeding, bile leak and hyperamylasemia in the observation was 14.3%, much lower than 30.4%(P＜0.05) in the control group. Conclusion Compared with EST treatment, the application of ESPBD in the treatment of patients with liver cirrhosis and choledocholithiasis is efficacious with high one-time successful rate of stone removal and less postoperative complications.

Key words: Choledocholithiasis, Liver cirrhosis, Limited endoscopic sphincterotomy with balloon dilation, Endoscopic sphincterotomy, Therapy

刘明, 王金婷, 杨士彦, 杨位轩, 万元春. ESPBD与EST治疗肝硬化合并胆总管结石患者疗效比较^*[J]. 实用肝脏病杂志, 2023, 26(6): 915-918.

Liu Ming, Wang Jinting, Yang ShiYan, et al. Efficacy comparison of ESPBD and EST in the treatment of compensated liver cirrhotics with choledocholithiasis[J]. Journal of Practical Hepatology, 2023, 26(6): 915-918.

参考文献

[1] Yu T, Yue YQ, Chen J, et al. Endoscopic papillary large balloon dilation with or without sphincterotomy for large bile duct stones removal: short-term and long-term outcomes. Hepatobiliary Pancreat Dis Int, 2020,19(4):404-406.
[2] Xu XD, Xu CF, Qian JQ, et al. Endoscopic papillary large balloon dilation with minor sphincterotomy for periampullary diverticular papilla. Rev Esp Enferm Dig, 2019,111(12):935-940.
[3] 林岩,严俊,张奇煜,等.失代偿期肝硬化合并胆总管结石患者行十二指肠镜治疗的安全和有效性分析.中华消化内镜杂志,2019,36(6):416-421.
[4] Alsenbesy M, Shahat K, Nawara A, et al. Endoscopic papillary large balloon dilatation for the extraction of common bile duct stones. Rev Esp Enferm Dig, 2019,111(5):358-363.
[5] Haseeb A, Freeman ML. Endoscopic papillary large balloon dilation versus endoscopic sphincterotomy for treatment of bile duct stones. Curr Treat Options Gastroenterol, 2019,17(2):221-230.
[6] 冯浩,李顺宗,王子伟.LCBDE与EST联合LC治疗胆囊结石合并胆总管结石患者疗效及安全性分析.实用肝脏病杂志,2022,25(1):120-123.
[7] Hakuta R, Kawahata S, Kogure H, et al. Endoscopic papillary large balloon dilation and endoscopic papillary balloon dilation both without sphincterotomy for removal of large bile duct stones: a propensity-matched analysis. Dig Endosc, 2019,31(1):59-68.
[8] Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol, 2016,51(7):629-650.
[9] 付前广,李倩,冯小雪,等.腹腔镜胆总管探查术联合腹腔镜胆囊切除术治疗胆囊结石合并胆总管结石患者临床疗效研究.实用肝脏病杂志,2021,24(4):589-592.
[10] Kogure H, Kawahata S, Mukai T, et al. Multicenter randomized trial of endoscopic papillary large balloon dilation without sphincterotomy versus endoscopic sphincterotomy for removal of bile duct stones: marvelous trial. Endoscopy, 2020,52(9):736-744.
[11] Tringali A, Rota M, Rossi M, et al. A cumulative meta-analysis of endoscopic papillary balloon dilation versus endoscopic sphincterotomy for removal of common bile duct stones. Endoscopy, 2019,51(6):548-559.
[12] Saito H, Imamura H, Matsushita I, et al. Immediate or interval endoscopic papillary large-balloon dilation after limited endoscopic sphincterotomy for bile duct stone removal. Intern Med, 2021,60(17):2713-2718.
[13] Iwano K, Kurita A, Mori Y, et al. Endoscopic papillary large balloon dilation for pancreatic duct stone: a first report. Endoscopy, 2020,52(6):213-214.
[14] Wang X, Wang X, Sun H, et al. Endoscopic papillary large balloon dilation reduces further recurrence in patients with recurrent common bile duct stones: a randomized controlled trial. Am J Gastroenterol, 2022,117(5):740-747.
[15] 翁胜,刘志民.两种手术方法对复发性胆总管结石患者血液炎症指标和免疫功能的影响.中华普外科手术学杂志(电子版),2020,14(4):399-402.
[16] Park JS, Jeong S, Lee DK, et al. Comparison of endoscopic papillary large balloon dilation with or without endoscopic sphincterotomy for the treatment of large bile duct stones. Endoscopy, 2019,51(2):125-132.
[17] Ishii S, Fujisawa T, Ushio M, et al. Evaluation of the safety and efficacy of minimal endoscopic sphincterotomy followed by papillary balloon dilation for the removal of common bile duct stones. Saudi J Gastroenterol, 2020,26(6):344-350.
[18] Murabayashi T, Kanno Y, Koshita S, et al. Long-term outcomes of endoscopic papillary large-balloon dilation for common bile duct stones. Intern Med, 2020,59(7):891-899.
[19] Liu SS, Chang XH, Song JT, et al. Risks of postendoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia after endoscopic papillary balloon dilation: a retrospective analysis. Surg Laparosc Endosc Percutan Tech,2019,29(4):280-284.
[20] Lee GH, Yang MJ, Kim JH, et al. Balloons larger than 15 mm can increase the risk of adverse events following endoscopic papillary large balloon dilation. J Gastroenterol Hepatol, 2019,34(8):1450-1453.

ESPBD与EST治疗肝硬化合并胆总管结石患者疗效比较^*

Efficacy comparison of ESPBD and EST in the treatment of compensated liver cirrhotics with choledocholithiasis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.
[2]	宋涛, 徐敏, 党子龙, 孙珺珺. 恩替卡韦联合α-干扰素治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 785-788.
[3]	高丽娟, 李永库, 董新颖, 杨艺宁, 冷雪君. 艾米替诺福韦治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 789-792.
[4]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[5]	曹汴川, 刘梅, 丁苹, 汤玲毓, 郭明贤, 周仙, 袁天茹, 严一凯, 黄富礼, 黄永茂. 格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 801-804.
[6]	王卓雅, 吴洋鹏, 黄益桃. 还原型谷胱甘肽联合护肝清脂片治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 823-826.
[7]	陈雅君, 朱婧, 李璐, 何钦. 标准免疫抑制疗法联合异甘草酸镁治疗自身免疫性肝炎患者外周血B细胞和调节性B细胞变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 835-838.
[8]	杨开宁, 王梦梦, 王占坤, 陈秀秀, 肖剑, 王永丽. 注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 839-842.
[9]	王新月, 周莉, 董金玲, 陈煜. 双重血浆分子吸附系统治疗肝衰竭患者应用甲磺酸萘莫司他与肝素抗凝有效性与安全性比较研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 843-846.
[10]	邹涛, 张敏, 杨凡, 王丽, 喻峰. 慢性乙型肝炎和乙型肝炎肝硬化患者PBMCs 信号转导和转录激活因子3及血清可溶性CD30分子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 855-858.
[11]	田宇, 陈燕, 曹佳非, 周晓倩. 肝硬化并发肝肾综合征患者U-mAl及外周血NLR和血清NGAL水平变化研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 859-862.
[12]	姜亚超, 尹力, 颜状. “改良三明治夹心法”行ESVD术治疗肝硬化并发食管胃静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 863-866.
[13]	刘欢, 陈鹏, 蒯文涛, 徐亮. 肝脏硬度测定、血小板计数/脾厚比值和脾静脉直径预测肝硬化并发食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 867-870.
[14]	贺梅年, 赵思佳, 田智超, 何秀英, 巴正武. 超声半定量评分结合弹性成像诊断慢性乙型肝炎患者早期肝硬化临床价值分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 871-874.
[15]	杨帆, 张小娟, 李丹, 姜莎莎, 张亮, 唐伟, 赵微. 胃镜下硬化术联合组织胶注射术治疗乙型肝炎肝硬化并发食管胃静脉曲张破裂出血患者1年再出血危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 875-878.